ArticleJournal of ophthalmic inflammation and infection2026
Toxoplasma gondii retinochoroiditis associated with Epstein-Barr virus-induced retinal necrosis in an immunocompetent patient.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe a rare case of concomitant Toxoplasma gondii (Tg) retinochoroiditis and Epstein-Barr virus (EBV) retinal necrosis in an immunocompetent patient, successfully treated with a combined intravitreal and systemic therapeutic approach.
methodsA 52-year-old immunocompetent woman with recurrent bilateral Tg retinochoroiditis presented with reactivation in the left eye unresponsive to standard antiparasitic therapy. Comprehensive ophthalmological examination, including diagnostic pars plana vitrectomy with vitreous biopsy and polymerase chain reaction (PCR) analysis, was performed.
resultsPCR analysis of the vitreous sample confirmed the presence of both Tg and EBV. Intravitreal methotrexate (MTX) was initiated and administered over an 8-week period in combination with ongoing intravitreal clindamycin and systemic antiparasitic therapy, together with systemic acyclovir (800 mg three times daily). The patient demonstrated progressive clinical improvement, with stabilization of visual acuity and retinal morphology on optical coherence tomography (OCT). Serial vitreous PCR monitoring revealed a gradual decline in Tg and EBV loads until both pathogens became undetectable. No recurrence occurred during follow-up.
conclusionThis report describes a rare case of Tg-EBV coinfection-related retinochoroiditis in an immunocompetent patient. The favorable outcome observed after initiation of intravitreal MTX, in combination with systemic acyclovir, suggests that MTX may have contributed to disease control through immunomodulatory suppression of B-cell proliferation and possible antiviral effects. This case underscores the importance of considering coinfection in atypical or treatment-refractory retinochoroiditis, even in immunocompetent hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.